Literature DB >> 21247518

Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation.

Keiko Nakagawa1, Tadakazu Hirai, Shutaro Takashima, Nobuyuki Fukuda, Kazumasa Ohara, Etsuko Sasahara, Yoshiharu Taguchi, Nobuhiro Dougu, Takashi Nozawa, Kortaro Tanaka, Hiroshi Inoue.   

Abstract

Chronic kidney disease is a risk factor for cardiovascular events, but how it relates to the prognosis associated with clinical risk factors for thromboembolism in patients with nonvalvular atrial fibrillation (AF) is not well known. Estimated glomerular filtration rate (eGFR), score for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke/transient ischemic attack (CHADS(2)), and clinical outcomes of cardiovascular events were determined in 387 patients with nonvalvular AF (mean age 66 years, 289 men, mean follow-up 5.6 ± 3.2 years). Decreased eGFR (<60 ml/min/1.73 m(2)) combined with CHADS(2) score ≥2 was associated with higher all-cause (12.9% vs 1.4% per year, hazard ratio [HR] 6.9, p <0.001) and cardiovascular (6.5% vs 0.2% per year, HR 29.7, p <0.001) mortalities compared to preserved eGFR (≥60 ml/min/1.73 m(2)) combined with CHADS(2) score <2. This was also true for rates of cardiac events (cardiac death, nonfatal myocardial infarction, or hospitalization for worsening of heart failure, 10.4% vs 1.3% per year, HR 8.9, p <0.001), ischemic stroke (3.6% vs 0.2% per year, HR 11.0, p <0.001), and cardiovascular events (cardiac events and ischemic stroke, 13.6% vs 1.5% per year, HR 8.3, p <0.001). On multivariate analysis, CHADS(2) score ≥2, decreased eGFR, and male gender independently predicted all-cause mortality. In conclusion, combined eGFR and CHADS(2) score could be an independent powerful predictor of cardiovascular events and mortality in patients with nonvalvular AF. Long-term mortality, cardiac events, and stroke risk were >8 times higher when decreased eGFR (<60 ml/min/1.73 m(2)) was present with higher CHADS(2) score (≥2).
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21247518     DOI: 10.1016/j.amjcard.2010.10.074

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  31 in total

Review 1.  Preoperative Noncoronary Cardiovascular Assessment and Management of Kidney Transplant Candidates.

Authors:  Jayson Rakesh Baman; Joseph Knapper; Zankhana Raval; Matthew E Harinstein; John J Friedewald; Kameswari Maganti; Michael J Cuttica; Michael I Abecassis; Ziad A Ali; Mihai Gheorghiade; James D Flaherty
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-25       Impact factor: 8.237

Review 2.  Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Authors:  Robert G Hart; John W Eikelboom; Alistair J Ingram; Charles A Herzog
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

Review 3.  Chronic Kidney Disease and Atrial Fibrillation: A Contemporary Overview.

Authors:  Nitin Kulkarni; Nilusha Gukathasan; Samantha Sartori; Usman Baber
Journal:  J Atr Fibrillation       Date:  2012-06-15

Review 4.  Management of cardiovascular disease in patients with kidney disease.

Authors:  Mark R Kahn; Michael J Robbins; Michael C Kim; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2013-02-19       Impact factor: 32.419

5.  CHADS2, CHA2DS2-VASc and R2CHADS2 scores predict mortality in patients with coronary artery disease.

Authors:  Fang-Yang Huang; Bao-Tao Huang; Xiao-Bo Pu; Yong Yang; Shi-Jian Chen; Tian-Li Xia; Yi-Yue Gui; Yong Peng; Rui-Shuang Liu; Yuanweixiang Ou; Fei Chen; Ye Zhu; Mao Chen
Journal:  Intern Emerg Med       Date:  2017-02-04       Impact factor: 3.397

6.  Glomerular filtration rate: A prognostic marker in atrial fibrillation-A subanalysis of the AntiThrombotic Agents Atrial Fibrillation.

Authors:  Riccardo Proietti; Lucio Gonzini; Giovanni Pizzimenti; Antonietta Ledda; Pietro Sanna; Ahmed AlTurki; Vincenzo Russo; Mauro Lencioni
Journal:  Clin Cardiol       Date:  2018-12-04       Impact factor: 2.882

Review 7.  Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease.

Authors:  Nileshkumar J Patel; Aashay Patel; Kanishk Agnihotri; Dhaval Pau; Samir Patel; Badal Thakkar; Nikhil Nalluri; Deepak Asti; Ritesh Kanotra; Sabeeda Kadavath; Shilpkumar Arora; Nilay Patel; Achint Patel; Azfar Sheikh; Neil Patel; Apurva O Badheka; Abhishek Deshmukh; Hakan Paydak; Juan Viles-Gonzalez
Journal:  World J Cardiol       Date:  2015-07-26

8.  Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatment.

Authors:  Yun-Li Xing; Qing Ma; Xiao-Ying Ma; Cui-Ying Wang; Zhen Zhou; Ying-Shuo Huang; Ying Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 9.  Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease.

Authors:  Yazan Khouri; Tiona Stephens; Gloria Ayuba; Hazim AlAmeri; Nour Juratli; Peter A McCullough
Journal:  J Atr Fibrillation       Date:  2015-04-30

10.  Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation.

Authors:  Medha Airy; Jesse D Schold; Stacey E Jolly; Susana Arrigain; Nisha Bansal; Wolfgang C Winkelmayer; Joseph V Nally; Sankar D Navaneethan
Journal:  Am J Nephrol       Date:  2018-07-26       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.